Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

AMNF
Sort by: Date|Relevance

Find Out Why this Uranium Junior Mining Company Has a Distinctive Competitive Advantage

Skyharbour Resources (TSX.V: SYH | OTCQB: SYHBF) Jordan Trimble the CEO of Skyhabour Resources sits down with Maurice Jackson of Proven and Probable to discuss a number of catalyst’s that are emerging in the uranium ...
Maurice Jackson | April 3, 2020 |

Is a Local Top in Gold At Hand?

In yesterday’s analysis on gold price in December 2019 , we wrote that while the outlook for the yellow metal for the following months was bearish, it was bullish for the short term. And indeed – gold, silver, and mining stocks rallied. In fact, the rally cont...
Przemyslaw Radomski, CFA | December 5, 2019 |

Westhaven’s robust economics are a solid foundation to expand gold-silver inventory

In the heart of British Columbia, a new study has illuminated a high-grade gold project with immense potential right off a highway. The findings indicate a compelling low-cost, high-margin opportunity that has captured the attention of investors seeking exceptional return...
Research | July 24, 2023 |

Colombian Mines gearing up for a busy drilling campaign

It has been a reasonably good run for resources companies as improving world economies have infused some buying interest. While companies have taken numerous steps to expand their resource estimates, only those with sound investment cases have been successful in securing fin...
Sam Kiri, CFA ACMA | October 28, 2012 |

The Gold Play That’s Poised for a Breakout 2022

With the spot price of gold hovering around USD$2000 and inflation soaring, savvy metals & mining investors are looking for real value and opportunity in the precious metals exploration space. And, it’s gold that has historically provided the most proven tra...
Dave Jackson | April 27, 2022 |

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials

InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. Vancouver-based clinical stage biopharmaceutical company InMed Pharmaceuticals Inc. (IN:TSX; IMLFF:OTCQX) , which is engaged in...
Streetwise Reports | January 21, 2020 |

Stock Bottom Reached? Don’t Bet the Farm Just Yet

As the markets grapple with the coronavirus story, the stock market is no exception. Jittery and volatile trading is what we’ve seen on Friday, January 24 already. In the heat of the moment, it’s easy to sell first and ask questions later. But t...
Monica Kingsley | February 4, 2020 |

Stock Bottom Reached? Don’t Bet the Farm Just Yet

As the markets grapple with the coronavirus story, the stock market is no exception. Jittery and volatile trading is what we’ve seen on Friday, January 24 already. In the heat of the moment, it’s easy to sell first and ask questions later. But t...
Monica Kingsley | February 7, 2020 |

Immunomedics Shares Double as Phase 3 Breast Cancer Trial Achieves 'Compelling' Efficacy Data

Shares of Immunomedics opened 117% higher after the company reported that it has stopped its Phase 3 ASCENT study of sacituzumab govitecan after recording "compelling evidence of efficacy" in heavily pretreated patients with metastatic triple-negative breast cancer. ...
Streetwise Reports | April 7, 2020 |

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...
Streetwise Reports | May 28, 2020 |
1 2 3 4 5 6 7